Advertisement

An Alternative Route — within a Major Company: Selling Out, but for Greater Resources and Security

  • Stephanie Jones

Abstract

‘One of my reasons for leaving Texas Instruments, Abbott Laboratories and Allied Corporation to head up Biogen was to get away from the mega-corporation lifestyle. I’m conscious that there’s some tendency for some biotechnology companies to be taken over by big corporates. We’ve seen how Genentech have sold out a portion of their shares to Hoffman-La Roche. If I think about Biogen’s prospects for continued independence, I’d say that I think biotechnology companies — not unlike the last 30 years of other high technology industries that have developed — as high technology emerging growth companies, can stay independent if they want to.

Keywords

Venture Capital Alternative Route Biotechnology Company Biotech Company Major Company 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© International Business Writing Limited 1992

Authors and Affiliations

  • Stephanie Jones

There are no affiliations available

Personalised recommendations